Anti-Selectin Blocker for Liver Ischemic Injury

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$719,044.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK061910-02
Award Id:
60888
Agency Tracking Number:
DK061910
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
135 WEST 41ST STREET SUITE 608, NEW YORK, NY, 10036
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
LUISTOLEDOPEREYRA
(269) 998-0134
LTOLEDO@BORGESS.COM
Business Contact:
GEORGEFALUS
(212) 719-4799
BIOMEDICAMC@NETSCAPE.NET
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), which occurs as the result of stroke, coronary ischemia, trauma and other related conditions. Compounds called selectins play an important role in this neutrophil-mediated injury. Drugs currently available for treatment have not resulted in optimal protective effects during clinical application. Preliminary studies in our laboratories already indicated that a recently discovered synthetic drug, TBC-1269, which acts as a selectin blocker, provides protection against tissue damage in rats subjected to severe liver ischemia/reperfusion. Our results from the completed Phase I feasibility studies (see Final Report in section C) indicated that TBC-1269 was significantly protective when given at the time of reperfusion and at a dose of 40 mg/kg, for animals undergoing severe (90 min) liver ischemia. Functional and histological parameters remained near-normal in animals receiving TBC-1269. During this proposed Phase II grant, we will expand our study of TBC-1269 to more precisely determine 1) the correct time and dosing for maximum drug effectiveness; 2) to compare the therapeutic value of TBC-1269 to other selectin blockers and selectin knockouts; 3) to evaluate the benefits of adding other drugs, such as anti-integrin beta 2-/alpha 4- and anti-TNF-alpha, to the treatment plan; and, 4) to examine potential cell signalling mechanisms (MAPK cascade). Results of this innovative study could significantly improve the clinical outcome for patients at risk for suffering from ischemial/reperfusion injuries. Treatment with TCB-1269 will enhance the quality of life of millions of patients suffering from the large number of maladies associated with ischemia/reperfusion ischemic maladies.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government